“…Treatment effects were dependent on baseline LPS levels, with increases in HDL and LDL particle size following therapy. Using Periodontal pathogens express HSPs such as HSP-60 (GroEL) Lu & McBride 1994, Maeda et al 1994, Vayssier et al 1994, Anti-Porphyromonas gingivalis GroEL and anti-Fusobacterium nucleatum GroEL, elevated in periodontitis patients, stimulates inflammatory cytokine production as well as monocyte and endothelial cell activation Ueki et al 2002, Lee et al 2012 Elevated levels in periodontitis patients, cross-reacts with oxidized low-density lipoproteins (oxLDL) and oral bacteria Schenkein et al 1999Schenkein et al , 2001Schenkein et al , 2004 Anti-oxLDL Locally produced in gingiva, found in GCF Schenkein et al 2004, Cross-react with P. gingivalis Rgp protease Turunen et al 2012, Higher in serum of periodontitis patients, and in periodontitis patients with CVD Montebugnoli et al 2004, Monteiro et al 2009 similar methodologies, they found that HDL promoted the enhanced efflux of cholesterol from macrophages following therapy, especially in patients in which CRP levels were also reduced by periodontal treatment (Pussinen et al 2004a). Kallio (Kallio et al 2008) observed that in periodontitis patients, elevated serum LPS levels persisted following therapy and that LPS was associated with highly atherogenic lipids, including vLDL and intermediate density lipoproteins (IDL).…”